Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have follicular lymphoma (grade 1-3A) or marginal zone lymphoma that is CD20-positive.
- You must have had at least one prior treatment that included a CD20-targeted antibody (like rituximab).
- You must have measurable disease on scans (e.g., a lymph node >1.5 cm or an enlarged spleen).
- You must need treatment because of symptoms like pain, fever, night sweats, or organ problems.
- You must be at least 18 years old and have adequate kidney, liver, and blood cell counts.
- You must not have had certain heart problems, active infections, or recent treatments like CAR-T therapy or a BTK inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.